Literature DB >> 15717940

Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with sidling blockade.

Ronald M Bukowski.   

Abstract

Entities:  

Year:  2005        PMID： 15717940     DOI： 10.1007/s11912-005-0032-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  10 in total

1.  Renal cell carcinoma: a priority malignancy for development and study of novel therapies.

Authors:  Robert J Motzer
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.

Authors:  A D Perera; E V Kleymenova; C L Walker
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.

Authors:  Keiichi Kondo; Masahiro Yao; Minoru Yoshida; Takeshi Kishida; Taro Shuin; Takeshi Miura; Masatoshi Moriyama; Kazuki Kobayashi; Naoki Sakai; Shigeki Kaneko; Satoshi Kawakami; Masaya Baba; Noboru Nakaigawa; Yoji Nagashima; Yukio Nakatani; Masahiko Hosaka
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

5.  Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

Authors:  Robert J Motzer; Robert Amato; Mary Todd; Wen-J Poo Hwu; Roger Cohen; Jose Baselga; Hyman Muss; Michael Cooper; Richard Yu; Michelle S Ginsberg; Michael Needle
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

6.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

Authors:  Mario Scartozzi; Italo Bearzi; Rossana Berardi; Alessandra Mandolesi; Guidalberto Fabris; Stefano Cascinu
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors:  Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

9.  Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

Authors:  C Langner; M Ratschek; P Rehak; L Schips; R Zigeuner
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

10.  Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?

Authors:  Janet E Dancey
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.